Environmental Contamination by SARS-CoV-2 During Noninvasive Ventilation in COVID-19.
COVID-19
aerosol-generating procedures
critical care
infection control
noninvasive ventilation
patient safety
Journal
Respiratory care
ISSN: 1943-3654
Titre abrégé: Respir Care
Pays: United States
ID NLM: 7510357
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
pmc-release:
01
01
2024
pubmed:
16
11
2022
medline:
28
12
2022
entrez:
15
11
2022
Statut:
ppublish
Résumé
Environmental contamination by SARS-CoV-2 from patients with COVID-19 undergoing noninvasive ventilation (NIV) in the ICU is still under investigation. This study set out to investigate the presence of SARS-CoV-2 on surfaces near subjects receiving NIV in the ICU under controlled conditions (ie, use of dual-limb circuits, filters, adequate room ventilation). This was a single-center, prospective, observational study in the ICU of a tertiary teaching hospital. Four surface sampling areas, at increasing distance from subject's face, were identified; and each one was sampled at fixed intervals: 6, 12, and 24 h. The presence of SARS-CoV-2 was detected with real-time reverse transcriptase-polymerase-chain-reaction (RT-PCR) test on environmental swabs; the RT-PCR assay targeted the SARS-CoV-2 virus nucleocapsid N1 and N2 genes and the human RNase P gene as internal control. In a total of 256 collected samples, none were positive for SARS-CoV-2 genetic material, whereas 21 samples (8.2%) tested positive for RNase P, thus demonstrating the presence of genetic material unrelated to SARS-CoV-2. Our data show that application of NIV in an appropriate environment and with correct precautions leads to no sign of surface environmental contamination. Accordingly, our data support the idea that use of NIV in the ICU is safe both for health care workers and for other patients.
Sections du résumé
BACKGROUND
Environmental contamination by SARS-CoV-2 from patients with COVID-19 undergoing noninvasive ventilation (NIV) in the ICU is still under investigation. This study set out to investigate the presence of SARS-CoV-2 on surfaces near subjects receiving NIV in the ICU under controlled conditions (ie, use of dual-limb circuits, filters, adequate room ventilation).
METHODS
This was a single-center, prospective, observational study in the ICU of a tertiary teaching hospital. Four surface sampling areas, at increasing distance from subject's face, were identified; and each one was sampled at fixed intervals: 6, 12, and 24 h. The presence of SARS-CoV-2 was detected with real-time reverse transcriptase-polymerase-chain-reaction (RT-PCR) test on environmental swabs; the RT-PCR assay targeted the SARS-CoV-2 virus nucleocapsid N1 and N2 genes and the human RNase P gene as internal control.
RESULTS
In a total of 256 collected samples, none were positive for SARS-CoV-2 genetic material, whereas 21 samples (8.2%) tested positive for RNase P, thus demonstrating the presence of genetic material unrelated to SARS-CoV-2.
CONCLUSIONS
Our data show that application of NIV in an appropriate environment and with correct precautions leads to no sign of surface environmental contamination. Accordingly, our data support the idea that use of NIV in the ICU is safe both for health care workers and for other patients.
Identifiants
pubmed: 36379641
pii: respcare.10323
doi: 10.4187/respcare.10323
pmc: PMC9993510
doi:
Substances chimiques
Ribonuclease P
EC 3.1.26.5
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-7Informations de copyright
Copyright © 2023 by Daedalus Enterprises.
Déclaration de conflit d'intérêts
The authors have disclosed no conflicts of interest.
Références
Int J Hyg Environ Health. 2020 Sep;230:113600
pubmed: 32799101
Emerg Infect Dis. 2020 Jul;26(7):1583-1591
pubmed: 32275497
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
JAMA. 2021 May 4;325(17):1731-1743
pubmed: 33764378
Ann Intensive Care. 2020 Oct 12;10(1):133
pubmed: 33044646
PLoS One. 2021 Jul 6;16(7):e0253875
pubmed: 34228727
J Pers Med. 2021 Sep 03;11(9):
pubmed: 34575661
Front Med (Lausanne). 2020 Jul 28;7:429
pubmed: 32850915
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Crit Care. 2021 Jul 30;25(1):268
pubmed: 34330320
JAMA Netw Open. 2021 Jul 1;4(7):e2120295
pubmed: 34236416
Sci Total Environ. 2020 Nov 10;742:140540
pubmed: 32619843
Lancet Public Health. 2022 Feb;7(2):e188-e194
pubmed: 35122760
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
JAMA. 2020 Jun 9;323(22):2329-2330
pubmed: 32329799
Chest. 2015 May;147(5):1336-1343
pubmed: 25392954
Eur Respir J. 2020 Nov 5;56(5):
pubmed: 32747398
J Infect. 2020 Aug;81(2):e1-e5
pubmed: 32360881
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
Clin Microbiol Infect. 2020 Aug;26(8):1094.e1-1094.e5
pubmed: 32450255
J Microbiol Immunol Infect. 2021 Feb;54(1):81-84
pubmed: 32425995
Thorax. 2022 Mar;77(3):259-267
pubmed: 34737194
ERJ Open Res. 2021 Dec 06;7(4):
pubmed: 34877350
Clin Infect Dis. 2022 Aug 24;75(1):e89-e96
pubmed: 35226740
J Infect Dis. 2022 Feb 1;225(3):385-391
pubmed: 34788831
Infect Control Hosp Epidemiol. 2021 Jun;42(6):669-677
pubmed: 33081858
BMJ Open Respir Res. 2020 Oct;7(1):
pubmed: 33040021
Infect Control Hosp Epidemiol. 2020 Nov;41(11):1258-1265
pubmed: 32507114
Respir Care. 2022 Aug;67(8):1022-1042
pubmed: 35387846
Braz J Microbiol. 2022 Mar;53(1):213-220
pubmed: 34993920